A new manufacturing process, developed by researchers at the Center for High-rate Nanomanufacturing (CHN) at Northeastern University, produces nanoparticle structures with a unique ability to pass through normal tissue boundaries.
Dr. Ahmed Busnaina, the Director of the CHN, has found that nano-sized particles can be fabricated into distinct shapes, such as nanopillars. With their controlled size and shape, these nanopillars could potentially have high tissue permeability.
This would create drug-loaded nanostructures with high tissue permeability, which could allow effective transport through the stomach. The nanostructures would then pass directly into the bloodstream. This would allow for oral delivery of poorly soluble drugs that are either currently undeliverable or are delivered through challenging ways.
The Technology Evaluation Consortium (TEC), managed by One Million Solutions in Health, is managing an evaluation within the pharmaceutical and biotech industry of the CNS nanoparticle structures.
The consortium is bringing together a number of industry leaders from pharmaceutical companies to evaluate, validate and further qualify the CHN’s patented process. Consortium members and pharma experts affiliated with the university will share ideas and solutions with the hopes of creating a likely path of adoption for Northeastern University’s nanoparticle technology.
